Heron Therapeutics (NASDAQ: HRTX) reported Q2 EPS of ($0.02), $0.01 worse than the analyst estimate of ($0.01). Revenue for the quarter came in at $37.2 million versus the consensus estimate of $38.08 million.

For earnings history and earnings-related data on Heron Therapeutics (HRTX) click here.